Advantage Alpha Capital Partners LP Lowers Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Advantage Alpha Capital Partners LP lessened its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 56.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,890 shares of the company’s stock after selling 11,477 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Kiniksa Pharmaceuticals were worth $176,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Braidwell LP lifted its position in Kiniksa Pharmaceuticals by 40.6% during the third quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after buying an additional 836,210 shares during the period. Parkman Healthcare Partners LLC boosted its position in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after acquiring an additional 108,102 shares during the last quarter. FMR LLC grew its holdings in Kiniksa Pharmaceuticals by 36,925.0% in the third quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after purchasing an additional 694,928 shares during the period. Jane Street Group LLC increased its position in Kiniksa Pharmaceuticals by 1,064.4% during the third quarter. Jane Street Group LLC now owns 345,092 shares of the company’s stock worth $8,624,000 after purchasing an additional 315,456 shares during the last quarter. Finally, Peregrine Capital Management LLC increased its position in Kiniksa Pharmaceuticals by 1.8% during the fourth quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company’s stock worth $4,827,000 after purchasing an additional 4,361 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $37.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Ragosa sold 36,372 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,766 shares of company stock valued at $2,011,735 in the last ninety days. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Shares of KNSA opened at $23.41 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The stock has a market cap of $1.70 billion, a PE ratio of -167.20 and a beta of 0.48. The stock’s 50-day moving average is $20.40 and its two-hundred day moving average is $22.00.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.35 earnings per share. On average, research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.